Biotest AG
Biotest AG: Biotest reports revenue of EUR 110 million in the first quarter 2017
DGAP-News: Biotest AG / Key word(s): Quarter Results / Biotest reports revenues of EUR 110.5 million in the first quarter 2017 Dreieich, 10 May 2017. In the first quarter of 2017, the Biotest Group generated sales of EUR 110.5 million, after EUR 133.6 million in the same period of the previous year. This corresponds to a percentage decrease of 17.3 %. EUR 26.5 million of this decrease is attributable to sales reductions from the recall of various batches of the product human albumin and resulting contractual penalties. The reason for the recall was a technical defect in the production of an intermediate product for human albumin, which has since been rectified. Without these one-time effects, there would have been a 2.5 % increase in sales to EUR 137.0 million, which would have been in line with the original guidance. EBIT of continuing operations amounted to EUR -24.9 million in the first quarter of 2017 compared to the previous year’s figure of EUR 17.0 million. In the core Therapy segment, EBIT of EUR -33.0 million was generated in the first three months of the 2017 financial year (previous year: EUR 9.4 million). This development was chiefly attributable to sales reductions of EUR 26.5 million from the anticipated return of human albumin already delivered and contractual penalties, one-time expenses from write-downs of EUR 9.1 million on inventories of the product human albumin that can no longer be sold due to technical problems in production, and other costs relating to the recall in the amount of EUR 1.7 million. In the first three months of the 2017 financial year, earnings after taxes of continuing operations in the amount of EUR -16.7 million (same period of the previous year: EUR 10.3 million) were impacted by the extraordinary items described above in connection with the recall of the product human albumin. Outlook: Due to the announced public offer we have postponed the Annual General Meeting to The Quarterly statement is available on the company’s website at
IR contact Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201 Disclaimer
10.05.2017 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |
Language: | English |
Company: | Biotest AG |
Landsteinerstraße 5 | |
63303 Dreieich | |
Germany | |
Phone: | 0 61 03 – 8 01-0 |
Fax: | 0 61 03 – 8 01-150 |
E-mail: | investor_relations@biotest.de |
Internet: | http://www.biotest.de |
ISIN: | DE0005227235, DE0005227201 |
WKN: | 522723, 522720 |
Indices: | SDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
End of News | DGAP News Service |